List of Excipients in Branded Drug NIMBEX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AbbVie Inc	NIMBEX	cisatracurium besylate	0074-4382	BENZENESULFONIC ACID
AbbVie Inc	NIMBEX	cisatracurium besylate	0074-4382	WATER

Nimbex Excipient Strategy and Commercial Opportunities for Cisatracurium Injection

Last updated: August 27, 2026

Nimbex is the branded injectable formulation of cisatracurium besylate, an intermediate-duration, nondepolarizing neuromuscular blocker used during surgery, intubation, and mechanical ventilation. Its commercial value is driven less by active-ingredient exclusivity than by sterile manufacturing, preservative selection, container compatibility, cold-chain control, and reliable hospital supply.

The strongest excipient opportunities are preservative-free presentations, ready-to-use infusion formats, improved stability at controlled room temperature, reduced extractables and leachables, and packaging designed for operating-room and intensive-care workflows. Generic competition has reduced the value of brand-level differentiation, but hospitals still pay for supply reliability, simplified preparation, and reduced medication-handling risk.

What is Nimbex and how is it formulated?

Nimbex contains cisatracurium besylate, the besylate salt of cisatracurium. It is supplied as a sterile intravenous injection and is administered by bolus injection or continuous infusion. The reference product has historically been supplied at a concentration of 2 mg/mL, with vial and premixed infusion presentations varying by market and product configuration. [1]

Product attribute	Nimbex commercial profile
Active ingredient	Cisatracurium besylate
Pharmacologic class	Nondepolarizing neuromuscular blocker
Route	Intravenous
Primary settings	Operating room, emergency intubation, intensive care
Typical concentration	2 mg/mL injection; premixed lower-concentration infusion products may also be marketed
Dosage form	Sterile aqueous injection or infusion
Storage sensitivity	Refrigerated storage is generally specified for cisatracurium injection products
Key excipient issue	Benzyl alcohol in certain multidose presentations; preservative-free alternatives have commercial value
Primary market	Institutional hospital market
Competitive structure	Generic injectable competition and contract-manufacturing supply

Nimbex is not an oral product and does not require solubilizers, suspending agents, taste masking, enteric protection, or modified-release excipients. The excipient strategy is therefore concentrated on parenteral safety, pH control, isotonicity, preservation, sterility, stability, and packaging.

What excipients are used in Nimbex injection?

The principal formulation components disclosed for cisatracurium injection products are water for injection, a pH-adjusting acid such as benzenesulfonic acid, and, in certain multidose configurations, benzyl alcohol as a preservative. Exact excipient composition depends on the presentation and labeling jurisdiction. [1,2]

Benzyl alcohol

Benzyl alcohol can provide antimicrobial preservation in multidose containers. Its use creates a tradeoff:

• It supports repeated-dose handling and multidose packaging.
• It introduces regulatory and clinical concerns for neonates, infants, and vulnerable patients.
• It may be less attractive for intensive-care protocols that prioritize preservative-free injectable products.
• It complicates product positioning in pediatric and neonatal formularies.

The commercial opportunity is not simply to remove benzyl alcohol. A preservative-free product must demonstrate container-closure integrity, sterility assurance, in-use stability, and suitable single-dose packaging.

Benzenesulfonic acid and pH control

Cisatracurium injection is formulated in an acidic range. A low-pH environment can support chemical stability but may create compatibility considerations when the drug is mixed with other intravenous products. pH control must be balanced against:

• Cisatracurium degradation during storage.
• Precipitation or incompatibility after dilution.
• Infusion-line compatibility.
• Patient tolerability during administration.
• Stability after vial puncture or preparation in a syringe or infusion bag.

The excipient and process design must preserve potency without introducing unnecessary buffering capacity that could alter compatibility.

Water for injection

Water for injection is the primary vehicle. Commercial differentiation depends on sterile processing, endotoxin control, fill-volume accuracy, container performance, and supply continuity rather than on the vehicle itself.

Dextrose or saline in premixed presentations

Premixed infusion products may use dextrose-containing or saline-based diluents depending on the manufacturer and approved presentation. These products can reduce bedside preparation, but they require validated stability data for the finished admixture, bag material, overwrap, and administration set. [2]

What formulation patents protect Nimbex?

Nimbex is unlikely to have meaningful current commercial protection from formulation patents in the United States. Cisatracurium was approved in the 1990s, and generic cisatracurium injections have entered the market. The primary competitive barriers are manufacturing quality, sterile supply, regulatory compliance, and hospital contracting rather than an active formulation patent estate.

Protection category	Current commercial relevance
Active-ingredient patent	Historical protection largely expired
Original product patent	No longer a major barrier to generic entry
Formulation patent	Limited visible market significance for current US competition
Method-of-use patent	Low practical relevance to hospital generic entry
FDA exclusivity	Historical exclusivity has expired
Biosimilar protection	Not applicable because cisatracurium is a synthetic small molecule
Regulatory barriers	High relative to the low unit value of the product
Manufacturing barriers	Significant because the product is sterile, refrigerated, and injectable

The FDA Orange Book remains the controlling source for current listed patents and exclusivity information. [3] A commercial diligence review should distinguish between patents listed for the original NDA, patents covering cisatracurium chemistry, and patents that could actually block an abbreviated new drug application. Historical patents that no longer affect approval or launch should not be treated as current barriers.

When does Nimbex lose exclusivity?

Nimbex has already lost its meaningful US regulatory and market exclusivity. Generic cisatracurium products are available, and the commercial market is governed by hospital purchasing, manufacturer reliability, product availability, and pricing.

Paragraph IV challenges

Paragraph IV litigation is not the principal current risk for Nimbex. The product's age and generic availability mean that future entrants are more likely to rely on established abbreviated approval pathways than to trigger a commercially material patent dispute.

A Paragraph IV filing could still arise if a manufacturer identifies a newly listed patent or pursues a patent-protected formulation, container, or delivery configuration. That scenario would be more relevant to an improved product than to conventional cisatracurium injection.

Settlement agreements

No settlement agreement is a central market driver for current cisatracurium supply. Any historical patent settlement should be evaluated against its expiration date, the specific dosage form covered, and whether it affected only an early generic entrant. A settlement that has expired does not create current launch protection.

What FDA regulatory status does Nimbex have?

Nimbex is an FDA-approved prescription injectable product. Cisatracurium generic products are approved through the abbreviated new drug application pathway when they demonstrate pharmaceutical equivalence, bioequivalence where applicable, and compliance with injectable-product quality requirements. [1,4]

The FDA regulatory burden remains substantial because applicants must control:

• Sterility and bacterial endotoxins.
• Assay, impurities, and degradation products.
• Container-closure integrity.
• pH and osmolality.
• Particulate matter.
• Refrigerated storage and shipping.
• In-use stability after vial entry or dilution.
• Compatibility with infusion systems.
• Labeling for preservative content and vulnerable populations.

The product is not a biologic. Biosimilar competition, interchangeability designations, and biologic patent dance procedures do not apply.

What excipient strategies create commercial opportunities?

1. Preservative-free single-dose vials

A preservative-free vial is the clearest formulation opportunity. It can be positioned for operating rooms, intensive-care units, pediatric use, and institutions with policies that limit benzyl alcohol exposure.

The commercial advantages include:

• Reduced preservative-related clinical concern.
• Better alignment with neonatal and pediatric protocols.
• Simplified formulary review.
• Lower risk of medication-selection errors between preserved and preservative-free products.
• Potential use in automated dispensing systems.

The disadvantages are higher packaging consumption, greater waste from unused contents, and the need for robust single-dose sterility controls.

2. Ready-to-use infusion bags

A ready-to-use cisatracurium infusion product can reduce pharmacy compounding and bedside dilution. The value is strongest where hospitals face shortages of pharmacy labor or seek to reduce preparation errors.

A differentiated product could use:

• Standardized concentrations.
• Clearly labeled infusion bags.
• Barcode-ready packaging.
• Low-sorbing bag materials.
• Extended refrigerated and in-use stability.
• Overwraps that protect against light and handling damage.

The principal development risk is demonstrating stability in the final container and administration system rather than only in the original vial.

3. Room-temperature stability

Cisatracurium products commonly require refrigerated storage. A formulation or packaging system that supports longer room-temperature excursions could create value for emergency departments, ambulances, operating-room cabinets, and hospitals with limited cold-chain capacity.

Potential approaches include:

• Improved pH control.
• Chelator evaluation where justified by impurity data.
• Oxygen-control packaging.
• Low-permeability container materials.
• Lyophilized or concentrated presentations, subject to reconstitution burden.
• Validated excursion labeling.

Any room-temperature claim must be supported by real-time and accelerated stability data. A short temporary excursion allowance may have commercial value even if full room-temperature storage is not achievable.

4. Low-volume, high-concentration presentations

A more concentrated product could reduce infusion volume and simplify transport. The opportunity is constrained by dose-measurement risk, local irritation, pump accuracy, and compatibility with standard hospital protocols.

A concentrated formulation is most commercially attractive for intensive-care use, where prolonged infusions can consume substantial bag volume. It is less attractive if it requires new pump settings or creates a meaningful risk of tenfold dosing errors.

5. Packaging and device integration

The excipient composition may be unchanged while the presentation improves. Commercially relevant packaging options include:

• Ready-to-administer syringes.
• Unit-dose vials with barcodes.
• Dual-label formats for operating-room and pharmacy workflows.
• Tamper-evident packaging.
• Small-volume bags for continuous infusion.
• Packaging optimized for automated dispensing cabinets.

These improvements may be protectable through device, packaging, or process patents, although their practical value depends on hospital adoption and procurement preferences.

How does Nimbex compare with competing neuromuscular blockers?

Nimbex competes with atracurium, rocuronium, vecuronium, and succinylcholine. Its commercial position is based on clinical preference, organ-independent elimination characteristics, procurement price, and supply reliability.

Product	Main commercial distinction	Excipient opportunity
Cisatracurium/Nimbex	Intermediate duration; Hofmann elimination contributes to clearance	Preservative-free, ready-to-use, stability, packaging
Atracurium	Similar clinical category; histamine-related tolerability considerations	Same sterile injectable opportunities, with differentiation through supply and formulation
Rocuronium	Rapid onset and broad use in emergency airway management	Higher-value ready-to-use and prefilled formats
Vecuronium	Intermediate-duration neuromuscular blockade	Reconstitution and ready-to-use convenience
Succinylcholine	Rapid onset and short duration	Ready-to-administer systems and shortage resilience

Cisatracurium has a defensible niche in patients for whom clinicians prefer its pharmacokinetic profile. The product does not have unlimited pricing power because hospitals can substitute among neuromuscular blockers based on protocol, inventory, and clinical setting.

What patent and IP opportunities exist for improved cisatracurium products?

The most credible IP opportunities are formulation and presentation claims rather than claims to cisatracurium itself.

Potential claim categories include:

1. A preservative-free cisatracurium composition with defined impurity limits.
2. A formulation stable at room temperature for a specified period.
3. A ready-to-use infusion bag with defined concentration and container material.
4. A low-sorption or low-extractables container-closure system.
5. A prefilled syringe with validated in-use stability.
6. A formulation with extended stability after dilution.
7. A packaging system that supports cold-chain excursion management.
8. A manufacturing process that reduces degradation products or particulate formation.

Patent strength would depend on unexpected stability, impurity control, compatibility, or clinical workflow benefits. A simple substitution of one pharmaceutically acceptable acid for another would face higher obviousness risk unless supported by comparative data.

Which companies are challenging Nimbex commercially?

The principal competitive threat comes from generic injectable manufacturers rather than branded innovators. Potential competitors include large generic and hospital-injectable suppliers such as Fresenius Kabi, Hikma, Sandoz, Pfizer's Hospira business, and other FDA-approved or regionally approved manufacturers, depending on market and current supply status. [4]

Competition is shaped by:

• FDA approval status.
• Manufacturing-site reliability.
• Drug-shortage history.
• Wholesale acquisition price.
• Hospital group purchasing organization contracts.
• Available vial sizes and concentrations.
• Preservative-free supply.
• Cold-chain execution.
• Ability to maintain supply during competitor disruption.

A small number of approved suppliers can still produce attractive commercial conditions if manufacturing failures or shortages constrain the market.

What generic entry risks exist for an improved Nimbex product?

A conventional generic cisatracurium injection faces low patent risk but substantial execution risk. An improved formulation faces the reverse profile: it may obtain differentiated IP but must prove that the improvement matters to hospitals.

The main risks are:

• FDA rejection of an unsupported formulation change.
• Failure to show stability in the marketed container.
• Incompatibility with infusion devices.
• Low clinical willingness to switch from inexpensive generics.
• Hospital resistance to new concentrations.
• Limited reimbursement for convenience-only improvements.
• Manufacturing costs that erase the price premium.
• Preservative-free waste from single-dose packaging.
• A competitor launching a similar ready-to-use product first.

Commercial success is most likely where the product solves a measurable operational problem, such as a documented shortage, pharmacy-compounding burden, cold-chain failure, or medication-preparation error.

What licensing deals could support a cisatracurium opportunity?

A licensing strategy would be more attractive for differentiated delivery or packaging technology than for the active ingredient. Relevant partners include:

• Sterile injectable contract manufacturers.
• Prefilled-syringe developers.
• Infusion-bag and container suppliers.
• Hospital injectable companies with established sales forces.
• Specialty pharmaceutical companies focused on anesthesia and critical care.
• Regional distributors with government-hospital contracts.

A licensing agreement should allocate responsibility for formulation development, container qualification, FDA supplements or ANDA submissions, pharmacovigilance, shortage reporting, and manufacturing-site changes. Royalty economics are likely to be modest for a standard generic and stronger for a product with enforceable formulation, device, or process claims.

How strong is the Nimbex patent estate?

The original Nimbex patent estate is commercially weak for current US market protection because the product is mature and generic competition exists. The stronger IP position would come from a new product architecture that combines:

• A clinically useful excipient profile.
• Reproducible stability improvement.
• A differentiated container or delivery device.
• A meaningful hospital workflow benefit.
• Patent claims supported by comparative data.
• Regulatory exclusivity or market protection attached to the improved product.

A formulation patent that merely recites known excipients at conventional concentrations would have limited defensive value. Claims tied to specific degradation control, container interaction, or extended in-use stability would be more commercially relevant.

What is the revenue exposure for Nimbex-related products?

Nimbex is an institutional injectable, so revenue exposure depends on volume, contract pricing, and supply continuity rather than consumer brand loyalty. The largest revenue opportunities are likely to arise from:

• Hospital-wide contracts.
• Government procurement.
• Critical-care stocking agreements.
• Premium ready-to-use presentations.
• Products that reduce pharmacy labor.
• Supply agreements that protect against shortages.

A standard generic product is likely to compete primarily on price. A preservative-free or ready-to-use product can support a premium only if procurement teams can quantify savings from reduced preparation, lower error risk, reduced waste, or improved availability.

Key Takeaways

• Nimbex is cisatracurium besylate injection, a mature hospital injectable with generic competition.
• The main excipient issue is the use of benzyl alcohol in certain multidose presentations.
• Preservative-free single-dose products are the most direct formulation opportunity.
• Ready-to-use infusion bags and prefilled syringes offer stronger commercial differentiation than a conventional vial.
• Refrigerated storage creates a potential opportunity for improved room-temperature excursion stability.
• Nimbex does not face biosimilar competition because cisatracurium is a synthetic small molecule.
• Current market barriers are sterile manufacturing, quality systems, supply reliability, and hospital contracting.
• New patent value would likely come from formulation, container, process, or delivery claims.
• A commercial premium requires a measurable hospital workflow or safety benefit.
• Conventional generic entry has limited patent risk but high manufacturing and supply-chain risk.

FAQs About Nimbex Excipients and Commercial Strategy

Does Nimbex contain benzyl alcohol?

Certain multidose cisatracurium injection presentations use benzyl alcohol as a preservative. Product-specific labeling must be reviewed because preservative content can differ by vial type, manufacturer, and jurisdiction. [1,2]

Is preservative-free cisatracurium commercially attractive?

Yes. Preservative-free cisatracurium can target pediatric, neonatal, intensive-care, and operating-room protocols that prefer to avoid benzyl alcohol. The product must offset higher single-dose packaging and waste costs.

Can cisatracurium be reformulated for room-temperature storage?

Potentially, but the claim requires supporting stability data in the final container and under defined excursion conditions. pH control, oxygen exposure, container materials, and degradation-product formation are key development variables.

Are cisatracurium products eligible for biosimilar approval?

No. Cisatracurium is a synthetic small-molecule drug. Generic products use the abbreviated new drug application pathway rather than the biosimilar pathway.

What is the best commercial entry strategy for a new cisatracurium product?

The strongest strategy is a differentiated sterile injectable with a preservative-free profile, standardized ready-to-use concentration, barcode-enabled packaging, validated in-use stability, and reliable hospital supply. A low-price conventional vial would face direct competition from established generic manufacturers.

References

1. U.S. Food and Drug Administration. (n.d.). Nimbex (cisatracurium besylate) injection prescribing information. FDA-approved labeling.

2. National Library of Medicine. (n.d.). DailyMed: Cisatracurium besylate injection. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA and generic drug approvals. FDA.